胰腺癌的挑战
Challenges of Pancreatic Cancer.
作者信息
Dimastromatteo Julien, Houghton Jacob L, Lewis Jason S, Kelly Kimberly A
机构信息
From the *Biomedical Engineering Department, University of Virginia, Robert M. Berne Cardiovascular Research Center, Charlottesville, VA; †Department of Radiology and the Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY.
出版信息
Cancer J. 2015 May-Jun;21(3):188-93. doi: 10.1097/PPO.0000000000000109.
Abstract
The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.
摘要
近年来，新型分子癌症成像剂的研发取得了显著进展。众多癌症成像剂在临床前阶段已展现出在辅助诊断、分期及治疗规划方面的巨大潜力，这也促使一些成像剂获批进入人体试验阶段。胰腺导管腺癌是目前最致命的常见癌症，总体5年生存率约为6%。随着检测技术的进步，开发能够实现早期诊断的分子成像工具对于改善患者预后至关重要。在本综述中，我们将重点介绍能够照亮构成肿瘤的各种细胞群体的成像剂，即上皮、内皮和基质肿瘤细胞。
相似文献
1
Challenges of Pancreatic Cancer.胰腺癌的挑战
Cancer J. 2015 May-Jun;21(3):188-93. doi: 10.1097/PPO.0000000000000109.
2
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.循环肿瘤DNA作为检测胰腺癌的液体活检靶点。
World J Gastroenterol. 2016 Oct 14;22(38):8480-8488. doi: 10.3748/wjg.v22.i38.8480.
3
Early Cancer Detection at the Epithelial Surface.上皮表面的早期癌症检测
Cancer J. 2015 May-Jun;21(3):179-87. doi: 10.1097/PPO.0000000000000122.
4
New developments in the early diagnosis of pancreatic cancer.胰腺癌早期诊断的新进展
Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):149-156. doi: 10.1080/17474124.2017.1271323. Epub 2016 Dec 20.
5
Biomarkers for early diagnosis of pancreatic cancer.胰腺癌早期诊断的生物标志物。
Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):305-15. doi: 10.1586/17474124.2015.965145. Epub 2014 Nov 6.
6
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival.细胞融合增强了肿瘤异质性，并揭示了与肿瘤分期和生存相关的循环杂交细胞。
Sci Adv. 2018 Sep 12;4(9):eaat7828. doi: 10.1126/sciadv.aat7828. eCollection 2018 Sep.
7
Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications.胰腺癌患者循环肿瘤细胞的检测方法及临床意义。
Int J Cancer. 2014 Jan 1;134(1):1-8. doi: 10.1002/ijc.28134. Epub 2013 Mar 25.
8
The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.18-氟脱氧葡萄糖正电子发射断层扫描在胰腺癌同步放化疗后的鉴别诊断、分期及疗效评估中的临床应用价值。
J Clin Gastroenterol. 2006 Nov-Dec;40(10):923-9. doi: 10.1097/01.mcg.0000225672.68852.05.
9
Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes.胰腺癌早期检测的当前与未来趋势：分子靶点与PET探针
Curr Med Chem. 2015;22(29):3370-89. doi: 10.2174/0929867322666150821094015.
10
New strategies for the early detection of pancreatic cancer.胰腺癌早期检测的新策略。
Expert Rev Gastroenterol Hepatol. 2016;10(2):157-9. doi: 10.1586/17474124.2016.1122521. Epub 2015 Dec 14.
引用本文的文献
1
The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.长链非编码RNA和微小RNA在胰腺癌中的作用：聚焦于癌症的发生发展及其作为潜在生物标志物的作用
Front Oncol. 2024 Mar 15;14:1355064. doi: 10.3389/fonc.2024.1355064. eCollection 2024.
2
Drug Delivery Strategies for the Treatment of Pancreatic Cancer.用于治疗胰腺癌的药物递送策略
Pharmaceutics. 2023 Apr 22;15(5):1318. doi: 10.3390/pharmaceutics15051318.
3
C9orf16 represents the aberrant genetic programs and drives the progression of PDAC.C9orf16 代表了异常的遗传程序，并推动了 PDAC 的进展。
BMC Cancer. 2022 Oct 28;22(1):1102. doi: 10.1186/s12885-022-10202-5.
4
Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities.胰腺癌早期检测的成像模态：现状与未来研究机遇
Cancers (Basel). 2022 May 21;14(10):2539. doi: 10.3390/cancers14102539.
5
Modeling the mechanical stiffness of pancreatic ductal adenocarcinoma.胰腺导管腺癌的力学刚度建模
Matrix Biol Plus. 2022 Mar 21;14:100109. doi: 10.1016/j.mbplus.2022.100109. eCollection 2022 Jun.
6
ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.ERK 抑制可改善临床前胰腺导管腺癌的抗 PD-L1 免疫检查点阻断。
Mol Cancer Ther. 2021 Oct;20(10):2026-2034. doi: 10.1158/1535-7163.MCT-20-1112. Epub 2021 Aug 4.
7
Identification of Circ_001569 as a Potential Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer.环状 RNA circ_001569 作为胰腺癌诊断和预后潜在生物标志物的鉴定。
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033820983302. doi: 10.1177/1533033820983302.
8
Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.胰腺导管腺癌的预后生物标志物：一项伞状综述
Front Oncol. 2020 Sep 17;10:1466. doi: 10.3389/fonc.2020.01466. eCollection 2020.
9
Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides.噬菌体展示筛选、鉴定及新型胰腺癌靶向肽的特性分析。
Biomolecules. 2020 May 5;10(5):714. doi: 10.3390/biom10050714.
10
Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study.基于增强 CT 影像组学预测胰腺导管腺癌淋巴结转移的初步研究
Cancer Imaging. 2020 Jan 30;20(1):12. doi: 10.1186/s40644-020-0288-3.
本文引用的文献
1
A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts.一种用于人胰腺癌异种移植正电子发射断层显像的突变型抗CA19-9单链抗体片段-免疫球蛋白Fc段
Mol Imaging Biol. 2014 Oct;16(5):721-9. doi: 10.1007/s11307-014-0733-4.
2
Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer.由于在胰腺癌中的定位错误，支架蛋白 plectin 获得了意想不到的功能。
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19414-9. doi: 10.1073/pnas.1309720110. Epub 2013 Nov 11.
3
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.应用 PET 拓宽临床上已验证的用于肿瘤学的 CA19.9 血清生物标志物的诊断效用。
J Nucl Med. 2013 Nov;54(11):1876-82. doi: 10.2967/jnumed.113.119867. Epub 2013 Sep 12.
4
An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles.一种工程化的抗 CA19-9 cys-二抗，用于胰腺癌的正电子发射断层扫描成像和聚合脂质体纳米颗粒的靶向。
J Surg Res. 2013 Nov;185(1):45-55. doi: 10.1016/j.jss.2013.05.095. Epub 2013 Jun 19.
5
Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1.通过胸腺细胞分化抗原 1 的超声成像检测小鼠胰腺导管腺癌。
Gastroenterology. 2013 Oct;145(4):885-894.e3. doi: 10.1053/j.gastro.2013.06.011. Epub 2013 Jun 18.
6
Technologies for imaging the normal and diseased pancreas.正常胰腺和胰腺疾病的影像学技术。
Gastroenterology. 2013 Jun;144(6):1262-71.e1. doi: 10.1053/j.gastro.2013.01.076.
7
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.血清 CA 19-9 在胰腺腺癌的诊断、预后和管理中的临床应用：基于证据的评估。
J Gastrointest Oncol. 2012 Jun;3(2):105-19. doi: 10.3978/j.issn.2078-6891.2011.021.
8
Targeting claudin-4 in human pancreatic cancer.靶向人胰腺癌细胞中的紧密连接蛋白 4
Expert Opin Ther Targets. 2012 Sep;16(9):881-7. doi: 10.1517/14728222.2012.708340. Epub 2012 Jul 16.
9
Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.Claudin-4 靶向光学成像可检测胰腺癌及其前驱病变。
Gut. 2013 Jul;62(7):1034-43. doi: 10.1136/gutjnl-2012-302577. Epub 2012 Jun 7.
10
Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.血清 CA19-9 是预测胰腺腺癌切除术后早期复发的术前参数之一。
J Gastrointest Surg. 2012 May;16(5):977-85. doi: 10.1007/s11605-012-1859-9. Epub 2012 Mar 13.
Zotero 插件